Portal de Periódicos da CAPES

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1997; Lippincott Williams & Wilkins; Volume: 15; Issue: 4 Linguagem: Inglês

10.1200/jco.1997.15.4.1318

1527-7755

Sandra M. Swain, Fredrick S. Whaley, Mirjam C. Gerber, Stuart P. Weisberg, Michael York, Darcy Spicer, Sarah E. Jones, Scott Wadler, Anjali Desai, Charles L. Vogel, James L. Speyer, A Mittelman, Salitha Reddy, Kelly Pendergrass, E Vélez-García, Michael S. Ewer, J. R. Bianchine, Richard A. Gams,

Chemotherapy-related skin toxicity

PURPOSE To determine the cardioprotective effect of dexrazoxane (DZR) used in a doxorubicin-based combination therapy in advanced breast cancer. PATIENTS AND METHODS Between November 1988 and January 1991, 534 patients with advanced breast cancer were randomized to two multicenter, double-blind studies (088001 and 088006). Patients received fluorouracil, doxorubicin, and cyclophosphamide (FAC) with either DZR (DZR-to-doxorubicin ratio, 10:1) or placebo (PLA) every 3 weeks and were monitored with serial multiplegated acquisition (MUGA) scans. RESULTS The hazards ratio (HR) of PLA to DZR for a cardiac event, which was predefined ejection fraction changes or congestive heart failure (CHF), was 2.63 (95% confidence interval [CI], 1.61 to 4.27; P < .001) for 088001 and 2.00 (95% CI, 1.01 to 3.96; P = .038) for 088006. The objective response rates for 088001 were 46.8% for DZR and 60.5% for PLA, a difference of 14% (95% CI, -25% to -2%; P = .019), and for 088006 were 53.7% for DZR and 49.3% for PLA, a difference of 4% (95% CI, -13% to 22%; P = .63). Time to progression and survival were not significantly different between treatment arms in either study. Toxicities on the DZR arms included lower granulocyte and platelet counts at nadir (P = .009 and P = .004, respectively) and more pain on injection (P = .001), with no difference in the rates of fever, infection, or hemorrhage. CONCLUSION DZR had a significant cardioprotective effect as measured by noninvasive testing and clinical CHF. One of the two studies (088001) showed a lower response rate with DZR, but time to progression and survival were not significantly different. DZR is the first agent shown to reduce cardiotoxicity from doxorubicin.